NEW YORK, July 9, 2013 /PRNewswire/ -- SurePure, Inc. (OTCBB:SURP), a global leader in liquid photopurification, today announced that its proprietary photopurification technology has proven to be a viable alternative to the thermal pasteurization of human milk for milk banks in hospitals.
In research conducted at the Hartmann Human Lactation Research Group at the University of Western Australia, SurePure's photopurification technology delivered comparable microbiological purification without affecting essential enzymes and proteins. These enzymes and proteins include bile salt stimulated lipase (BSSL), alkaline phosphatase (AP), secretory IgA , lactoferrin, lysozyme, and are critical for the optimal development of neonates, especially amongst significantly premature infants.
Using a small trial unit, a simple adaptation of SurePure's commercial beverage-processing technology which has yet to be optimized for medical application, the equipment achieved 5-log reduction of total bacterial count. After small modifications of the unit it became possible to reduce the bacterial count to an undetectable (<5CFU/ml) level. More importantly the enzyme and protein work showed significant promise, with lipase retention of 100%, alkaline phosphatase retention of 100%, lysozyme of 75%, sIgA at 89%, lactoferrin at 87%, and no change in the bacteriostatic properties of fatty acids.
Says Steve Miller, VP Sales & Marketing at SurePure, "We are delighted with these preliminary results on human breast milk. This data is further evidence of the efficacy and safety of our unique photosterilization technology. After achieving solid results processing animal blood plasma, the results of this research evidences the untapped R&D and commercial potential of the technology in the medical and pharmaceutical arenas."
The full research can be accessed by clicking on <
|SOURCE SurePure, Inc.|
Copyright©2012 PR Newswire.
All rights reserved